Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Steyerberg, E. W.
Right arrow Articles by Habbema, J. D. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Steyerberg, E. W.
Right arrow Articles by Habbema, J. D. F.
(Radiology. 2000;215:437-444.)
© RSNA, 2000

Genitourinary Imaging

Retroperitoneal Metastases in Testicular Cancer: Role of CT Measurements of Residual Masses in Decision Making for Resection after Chemotherapy1

Ewout W. Steyerberg, PhD, H. Jan Keizer, MD, PhD, Dirk T. Sleijfer, MD, PhD, Sophie D. Fosså, MD, PhD, Dean F. Bajorin, MD, PhD, Arthur Gerl, MD, Ronald de Wit, MD, PhD, Wim J. Kirkels, MD, PhD, Heimen Schraffordt Koops, MD, PhD and J. Dik F. Habbema, PhD

1 From the Dept of Public Health, Center for Clinical Decision Sciences, Ee 2091, Erasmus University, PO Box 1738, 3000 DR Rotterdam, the Netherlands (E.W.S., J.D.F.H.); Dept of Clinical Oncology, Leiden University Medical Center, Netherlands (H.J.K.); Dept of Medical and Surgical Oncology, University Hospital Groningen, Netherlands (D.T.S., H.S.K.); Dept of Medical Oncology and Radiotherapy, Norwegian Radium Hospital, Oslo (S.D.F.); Dept of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY (D.F.B.); Dept of Internal Medicine III, Klinikum Grosshadern, University of Munich, Germany (A.G.); Dept of Medical Oncology, Rotterdam Cancer Institute, Netherlands (R.d.W.); and Dept of Urology, University Hospital Rotterdam, Netherlands (W.J.K.). Received Feb 22, 1999; revision requested Apr 28; final revision received Aug 23; accepted Sep 24. Address correspondence to E.W.S. (e-mail: steyerberg@mgz.fgg.eur.nl).

PURPOSE: To determine the relative importance of computed tomographic (CT) measurements for the prediction of histologic findings in residual masses in patients with nonseminomatous testicular cancer.

MATERIALS AND METHODS: Measurements of the maximum transverse size of retroperitoneal metastases before and after chemotherapy were available in 641 patients who underwent resection after chemotherapy while their levels of tumor markers were normal. Radiologic measurements of mass size and clinical characteristics (histologic findings in primary tumor and levels of {alpha}-fetoprotein, human chorionic gonadotropin, and lactate dehydrogenase before chemotherapy) were related to histologic findings in the residual mass with logistic regression analysis.

RESULTS: At resection, 302 patients had benign tissue, and 339 had residual tumor (mature teratomas or cancer). Tumor was more frequent in larger masses after chemotherapy but was unrelated to mass size before chemotherapy. Inclusion of the reduction in size significantly improved the logistic regression model, which included mass size after chemotherapy. This model was further improved with the addition of clinical characteristics. Areas under the receiver operating characteristic curves increased from 0.74 to 0.77 and 0.83 with these models.

CONCLUSION: A small retroperitoneal mass after chemotherapy is an important predictor of benign histologic findings in residual masses in patients with nonseminomatous testicular cancer. However, better predictions can be made when the reduction in size and clinical characteristics are considered as well. Decisions regarding resection should be based on the combination of these characteristics rather than on only mass size after chemotherapy.

Index terms: Abdomen, CT, 70.1211, 80.1211 • Neoplasms, diagnosis • Neoplasms, metastases, 80.1211, 87.33 • Receiver operating characteristic (ROC) curve • Teratoma, 847.313 • Testis, neoplasms, 847.313, 847.329




This article has been cited by other articles:


Home page
 JCOHome page
K. Oechsle, M. Hartmann, W. Brenner, S. Venz, L. Weissbach, C. Franzius, S. Kliesch, S. Mueller, S. Krege, R. Heicappell, et al.
[18F]Fluorodeoxyglucose Positron Emission Tomography in Nonseminomatous Germ Cell Tumors After Chemotherapy: The German Multicenter Positron Emission Tomography Study Group
J. Clin. Oncol., December 20, 2008; 26(36): 5930 - 5935.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Oldenburg, G. C. Alfsen, H. H. Lien, N. Aass, H. Waehre, and S. D. Fossa
Postchemotherapy Retroperitoneal Surgery Remains Necessary in Patients With Nonseminomatous Testicular Cancer and Minimal Residual Tumor Masses
J. Clin. Oncol., September 1, 2003; 21(17): 3310 - 3317.
[Abstract] [Full Text] [PDF]